Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01414426 · ClinicalTrials.gov registry record · Phase 2
Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions
A Phase 2 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT01414426 is a Phase 2 study that has completed, run by University of Chicago. The registered enrollment target is 20 participants.
The verdict
NCT01414426, a Phase 2 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This randomized phase II trial studies how well vandetanib works in preventing head and neck cancer in patients with precancerous head and neck lesions. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of vandetanib may keep cancer from forming in patients with premalignant lesions
Interventions
- OTHER laboratory biomarker analysis
- OTHER placebo
- PROCEDURE biopsy
- OTHER immunohistochemistry staining method
- DRUG vandetanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2012-01 |
| Est. Completion | 2019-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01414426
The ClinicalTrials.gov registry entry for NCT01414426 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT01414426 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01414426 about?
NCT01414426 is a clinical study titled "Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions". This randomized phase II trial studies how well vandetanib works in preventing head and neck cancer in patients with precancerous head and neck lesions. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of vandetanib may keep cancer from forming in patients with premal...
What is the current status of trial NCT01414426?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2012-01. Estimated completion is 2019-06-01.
What interventions are being tested in trial NCT01414426?
The interventions under investigation include: laboratory biomarker analysis (OTHER), placebo (OTHER), biopsy (PROCEDURE), immunohistochemistry staining method (OTHER), vandetanib (DRUG).
Who is sponsoring clinical trial NCT01414426?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.